{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:18:43Z","timestamp":1791825523727,"version":"4.3.4"},"reference-count":82,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R01 DA056771"],"award-info":[{"award-number":["R01 DA056771"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["U19 AI149646"],"award-info":[{"award-number":["U19 AI149646"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 AI152836"],"award-info":[{"award-number":["R21 AI152836"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.immuni.2023.07.003","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T10:29:55Z","timestamp":1690885795000},"page":"2408-2424.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Heavy-chain CDR3-engineered B cells facilitate in\u00a0vivo evaluation of HIV-1 vaccine candidates"],"prefix":"10.1016","volume":"56","author":[{"given":"Wenhui","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianling","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickolas","family":"Skamangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Bronkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Kobzarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinge","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava E.","family":"Allwardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasis","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Quinlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier W.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeryun","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Farzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2023.07.003_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.07.003_bib2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.07.003_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature12053","article-title":"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"Liao","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2023.07.003_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.virol.2012.10.004","article-title":"Broadly neutralizing antibodies against HIV-1: templates for a vaccine","volume":"435","author":"van Gils","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2023.07.003_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"Halper-Stromberg","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.07.003_bib6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2014.01.052","article-title":"Structural insights on the role of antibodies in HIV-1 vaccine and therapy","volume":"156","author":"West","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.07.003_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005864","article-title":"Sequential and simultaneous immunization of rabbits with HIV-1 envelope glycoprotein SOSIP.664 Trimers from Clades A, B and C","volume":"12","author":"Klasse","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2023.07.003_bib8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.immuni.2016.08.016","article-title":"HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies","volume":"45","author":"Steichen","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.07.003_bib9","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cell.2016.07.029","article-title":"Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires","volume":"166","author":"Tian","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.07.003_bib10","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.cell.2016.07.030","article-title":"Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice","volume":"166","author":"Escolano","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.07.003_bib11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nature10696","article-title":"Structure of HIV-1 gp120 V1\/V2 domain with broadly neutralizing antibody PG9","volume":"480","author":"McLellan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2023.07.003_bib12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.immuni.2015.10.014","article-title":"Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design","volume":"43","author":"Andrabi","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.07.003_bib13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.immuni.2017.03.017","article-title":"A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic beta-hairpin structure","volume":"46","author":"Lee","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.07.003_bib14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.celrep.2017.09.024","article-title":"Elicitation of neutralizing antibodies targeting the V2 apex of the HIV envelope trimer in a wild-type animal model","volume":"21","author":"Voss","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2023.07.003_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41586-019-0879-y","article-title":"Commonality despite exceptional diversity in the baseline human antibody repertoire","volume":"566","author":"Briney","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2023.07.003_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd2638","article-title":"Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth","volume":"371","author":"Roark","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.07.003_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001028","article-title":"A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals","volume":"6","author":"Walker","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2023.07.003_bib18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.1233989","article-title":"Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization","volume":"340","author":"Georgiev","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.07.003_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies","volume":"509","author":"Doria-Rose","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2023.07.003_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/JVI.01791-15","article-title":"New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency","volume":"90","author":"Doria-Rose","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2023.07.003_bib21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nsmb.2600","article-title":"Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16","volume":"20","author":"Pancera","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.immuni.2023.07.003_bib22","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex","volume":"111","author":"Sok","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2023.07.003_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 vaccines. HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"Sanders","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.07.003_bib24","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.1128\/JVI.01768-15","article-title":"Influences on the design and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers","volume":"89","author":"Ringe","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2023.07.003_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215106","article-title":"Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells","volume":"14","author":"Cupo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.immuni.2023.07.003_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006987","article-title":"HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies","volume":"14","author":"Richardson","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2023.07.003_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLOS Pathog."},{"key":"10.1016\/j.immuni.2023.07.003_bib28","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1128\/JVI.02652-15","article-title":"Structure-guided redesign increases the propensity of HIV env to generate highly stable soluble trimers","volume":"90","author":"Guenaga","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2023.07.003_bib29","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1084\/jem.20161160","article-title":"Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in\u00a0vivo","volume":"214","author":"Medina-Ram\u00edrez","year":"2017","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2023.07.003_bib30","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.immuni.2017.04.014","article-title":"Glycine substitution at helix-to-coil transitions facilitates the structural determination of a stabilized Subtype C HIV envelope glycoprotein","volume":"46","author":"Guenaga","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.07.003_bib31","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nsmb.3051","article-title":"Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 env","volume":"22","author":"Kwon","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.immuni.2023.07.003_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108432","article-title":"Automated design by structure-based stabilization and consensus repair to achieve prefusion-closed envelope trimers in a wide variety of HIV strains","volume":"33","author":"Rawi","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2023.07.003_bib33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.immuni.2017.04.021","article-title":"Particulate array of well-ordered HIV clade C env trimers elicits neutralizing antibodies that display a unique V2 cap approach","volume":"46","author":"Martinez-Murillo","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.07.003_bib34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.celrep.2015.03.047","article-title":"Cleavage-independent HIV-1 env trimers engineered as soluble native spike mimetics for vaccine design","volume":"11","author":"Sharma","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2023.07.003_bib35","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1128\/JVI.03451-14","article-title":"Single-chain soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env","volume":"89","author":"Georgiev","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2023.07.003_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau6769","article-title":"HIV-1 vaccine design through minimizing envelope metastability","volume":"4","author":"He","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.immuni.2023.07.003_bib37","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1016\/j.celrep.2018.08.051","article-title":"Rational design of DNA-expressed stabilized native-like HIV-1 envelope trimers","volume":"24","author":"Aldon","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2023.07.003_bib38","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/j.celrep.2016.07.074","article-title":"Holes in the glycan shield of the native HIV envelope are a target of trimer-elicited neutralizing antibodies","volume":"16","author":"McCoy","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2023.07.003_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12080-1","article-title":"Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle","volume":"10","author":"Brouwer","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2023.07.003_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10262-5","article-title":"Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence","volume":"10","author":"Sliepen","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2023.07.003_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02268-16","article-title":"Structure-based design of a soluble prefusion-closed HIV-1 env trimer with reduced CD4 affinity and improved immunogenicity","volume":"91","author":"Chuang","year":"2017","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2023.07.003_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.immuni.2023.07.003_bib43","first-page":"1","article-title":"Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates","volume":"6","author":"Saunders","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.immuni.2023.07.003_bib44","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41591-021-01574-5","article-title":"A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques","volume":"27","author":"Zhang","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2023.07.003_bib45","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1083\/jcb.151.2.F9","article-title":"HIV-1 membrane fusion: targets of\u00a0opportunity","volume":"151","author":"Doms","year":"2000","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.immuni.2023.07.003_bib46","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.cell.2015.11.056","article-title":"Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes","volume":"163","author":"de Taeye","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.07.003_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh2791","article-title":"Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization","volume":"7","author":"Turner","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.immuni.2023.07.003_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009736","article-title":"Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates","volume":"17","author":"van Schooten","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2023.07.003_bib49","doi-asserted-by":"crossref","first-page":"D413","DOI":"10.1093\/nar\/gku1056","article-title":"IMGT(R), the international ImMunoGeneTics information system(R) 25 years on","volume":"43","author":"Lefranc","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.immuni.2023.07.003_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00022","article-title":"Immunoglobulin and T\u00a0cell receptor genes: IMGT((R)) and the birth and rise of immunoinformatics","volume":"5","author":"Lefranc","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2023.07.003_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009807","article-title":"Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens","volume":"17","author":"Crooks","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2023.07.003_bib52","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.immuni.2022.09.003","article-title":"Membrane-bound mRNA immunogens lower the threshold to activate HIV env V2 apex-directed broadly neutralizing B cell precursors in humanized mice","volume":"55","author":"Melzi","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.07.003_bib53","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20190287","article-title":"HIV-specific humoral immune responses by CRISPR\/Cas9-edited B cells","volume":"216","author":"Hartweger","year":"2019","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2023.07.003_bib54","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.42995","article-title":"Reprogramming the antigen specificity of B cells using genome-editing technologies","volume":"8","author":"Voss","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.immuni.2023.07.003_bib55","first-page":"1","article-title":"Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells","volume":"11","author":"Huang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2023.07.003_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax0644","article-title":"B cells engineered to express pathogen-specific antibodies protect against infection","volume":"4","author":"Moffett","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2023.07.003_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19649-1","article-title":"Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion","volume":"11","author":"Nahmad","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2023.07.003_bib58","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41587-022-01328-9","article-title":"In\u00a0vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.immuni.2023.07.003_bib59","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ymthe.2021.10.027","article-title":"Reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire","volume":"30","author":"Ou","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.immuni.2023.07.003_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.052","article-title":"Structure of super-potent antibody CAP256-VRC26.25 in complex with HIV-1 envelope reveals a combined mode of trimer-apex recognition","volume":"31","author":"Gorman","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2023.07.003_bib61","doi-asserted-by":"crossref","first-page":"26523","DOI":"10.1073\/pnas.1909653116","article-title":"Approaching infinite affinity through engineering of peptide\u2013protein interaction","volume":"116","author":"Keeble","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2023.07.003_bib62","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1021\/acsnano.8b02805","article-title":"Engineering a rugged nanoscaffold to enhance plug-and-display vaccination","volume":"12","author":"Bruun","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.immuni.2023.07.003_bib63","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2106203118","article-title":"In\u00a0vitro affinity maturation of broader and more-potent variants of the HIV-1-neutralizing antibody CAP256-VRC26.25","volume":"118","author":"Yin","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2023.07.003_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00285-9","article-title":"Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying env trimers on two-component protein nanoparticles","volume":"6","author":"Brouwer","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.immuni.2023.07.003_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008665","article-title":"Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV env trimer immunogens","volume":"16","author":"Antanasijevic","year":"2020","journal-title":"PLOS Pathog."},{"key":"10.1016\/j.immuni.2023.07.003_bib66","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1016\/j.celrep.2017.11.016","article-title":"Soluble prefusion closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains","volume":"21","author":"Joyce","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2023.07.003_bib67","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00074-20","article-title":"Development of a 3mut-apex-stabilized envelope trimer that expands HIV-1 neutralization breadth when used to boost fusion peptide-directed vaccine-elicited responses","volume":"94","author":"Chuang","year":"2020","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2023.07.003_bib68","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.virol.2010.02.019","article-title":"Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function","volume":"401","author":"Eggink","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2023.07.003_bib69","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.cell.2021.01.035","article-title":"Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection","volume":"184","author":"Brouwer","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.07.003_bib70","series-title":"CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals","author":"Gristick","year":"2022"},{"key":"10.1016\/j.immuni.2023.07.003_bib71","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","article-title":"A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice","volume":"53","author":"Laczk\u00f3","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.07.003_bib72","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.immuni.2022.09.001","article-title":"Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors","volume":"55","author":"Willis","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2023.07.003_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06424-6","article-title":"Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation","volume":"9","author":"Johnson","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2023.07.003_bib74","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1073\/pnas.1004600107","article-title":"Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1","volume":"107","author":"Pejchal","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2023.07.003_bib75","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0092-8674(00)80577-2","article-title":"Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry","volume":"96","author":"Farzan","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.07.003_bib76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0092-8674(03)00508-7","article-title":"Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120","volume":"114","author":"Choe","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.07.003_bib77","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0076-6879(09)05407-X","article-title":"Chapter 7. Tyrosine sulfation of HIV-1 coreceptors and other chemokine receptors","volume":"461","author":"Choe","year":"2009","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.immuni.2023.07.003_bib78","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/bioinformatics\/18.5.769","article-title":"The Sulfinator: predicting tyrosine sulfation sites in protein sequences","volume":"18","author":"Monigatti","year":"2002","journal-title":"Bioinformatics"},{"key":"10.1016\/j.immuni.2023.07.003_bib79","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1126\/science.aad9195","article-title":"HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen","volume":"351","author":"Jardine","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.07.003_bib80","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1126\/science.aah3945","article-title":"Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice","volume":"353","author":"Sok","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2023.07.003_bib81","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.cell.2015.06.003","article-title":"Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice","volume":"161","author":"Dosenovic","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2023.07.003_bib82","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: Structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci"}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761323003163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761323003163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:22:23Z","timestamp":1761034943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761323003163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1074761323003163"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2023.07.003","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heavy-chain CDR3-engineered B cells facilitate in\u00a0vivo evaluation of HIV-1 vaccine candidates","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2023.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}